Ratings Nutex Health Inc.

Equities

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
0.6309 ^USD	-4.41%		-7.19%	-76.63%

May. 09	Earnings Flash (NUTX) NUTEX HEALTH Posts Q1 Revenue $67.5M	MT
May. 09	Nutex Health Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by -100% by 2026.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

	1st Jan change	Capi.	ESG Refinitiv
NUTEX HEALTH INC.	-76.63%	31.37M	-
HCA HEALTHCARE, INC.	+20.68%	85.55B	C+
CVS HEALTH CORPORATION	-29.31%	70.07B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.65%	29.06B	C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.63%	17.51B	B
FRESENIUS SE & CO. KGAA	+2.14%	17.39B	A-
QUEST DIAGNOSTICS INCORPORATED	+0.39%	15.38B	A-
REDE D'OR SÃO LUIZ S.A.	+6.47%	13.4B	B-
NATERA, INC.	+68.09%	12.87B	C-
FRESENIUS MEDICAL CARE AG	+6.43%	12.77B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality